Literature DB >> 7370919

Histologic features of tumors and the female superiority in survival from malignant melanoma.

H M Shaw, V J McGovern, G W Milton, G A Farago, W H McCarthy.   

Abstract

The primary tumors of 780 patients with clinical Stage I malignant melanoma were reviewed to seek reasons for the female superiority in survival. Histologic features of tumors believed to be of prognostic significance were examined: tumor thickness, evidence of regression, histogenetic type, and mitotic activity. The average tumor thickness was significantly less in women, due to a preponderance of very thin lesions in women and very thick lesions in men. In both men and women, there proved to be a direct correlation between five-year survival rate and tumor thickness, but women had a higher survival rate than men at each thickness level. These latter two findings, in combination, could contribute to the overall female superiority in survival. No further insight into the sex difference in survival was obtained from the examination of the other histologic features. Although the incidence of partial lesion regression was not markedly different except for very thin lesions. There were no disparities between the sexes in the incidences of histogenetic types or grades of mitotic activity, two histologic features which drew their prognostic significance only from their correlation with tumor thickness.

Entities:  

Mesh:

Year:  1980        PMID: 7370919     DOI: 10.1002/1097-0142(19800401)45:7<1604::aid-cncr2820450715>3.0.co;2-o

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  12 in total

1.  Gender-related differences in outcome for melanoma patients.

Authors:  Charles R Scoggins; Merrick I Ross; Douglas S Reintgen; R Dirk Noyes; James S Goydos; Peter D Beitsch; Marshall M Urist; Stephan Ariyan; Jeffrey J Sussman; Michael J Edwards; Anees B Chagpar; Robert C G Martin; Arnold J Stromberg; Lee Hagendoorn; Kelly M McMasters
Journal:  Ann Surg       Date:  2006-05       Impact factor: 12.969

2.  [Simultaneous enucleation of a pulmonary melanoma metastasis and myocardial revascularization].

Authors:  H Keller; R Hacker; M Stolte
Journal:  Med Klin (Munich)       Date:  1997-11-15

3.  Sex, pregnancy, hormones, and melanoma.

Authors:  I Jatoi; M E Gore
Journal:  BMJ       Date:  1993-07-03

4.  Should elective lymph node dissection be used for treatment of primary melanoma?

Authors:  B Biess; E B Bröcker; H Drepper; M Klein; A Lippold; A Peters
Journal:  J Cancer Res Clin Oncol       Date:  1989       Impact factor: 4.553

5.  A comparison of prognostic factors and surgical results in 1,786 patients with localized (stage I) melanoma treated in Alabama, USA, and New South Wales, Australia.

Authors:  C M Balch; S J Soong; G W Milton; H M Shaw; V J McGovern; T M Murad; W H McCarthy; W A Maddox
Journal:  Ann Surg       Date:  1982-12       Impact factor: 12.969

6.  Prognostic significance of the patient's sex, tumor site, and mitotic rate in thin (less than or equal to 1.5 mm) melanoma.

Authors:  C Kuehnl-Petzoldt; H Keil; E Schoepf
Journal:  Arch Dermatol Res       Date:  1984       Impact factor: 3.017

7.  Poor prognosis for malignant melanoma in Northern Ireland: a multivariate analysis.

Authors:  L G Gordon; W S Lowry; P J Pedlow; C C Patterson
Journal:  Br J Cancer       Date:  1991-02       Impact factor: 7.640

8.  Incidence of cutaneous malignant melanoma in Denmark 1978-1982. Anatomic site distribution, histologic types, and comparison with non-melanoma skin cancer.

Authors:  A Osterlind; K Hou-Jensen; O Møller Jensen
Journal:  Br J Cancer       Date:  1988-09       Impact factor: 7.640

9.  The incidence and pathogenesis of invasive cutaneous malignant melanoma in Northern Ireland.

Authors:  L G Gordon; W S Lowry
Journal:  Br J Cancer       Date:  1986-01       Impact factor: 7.640

10.  Bcl-2 expression is not associated with survival in metastatic cutaneous melanoma: a historical cohort study.

Authors:  Marília B Espíndola; Oly C Corleta
Journal:  World J Surg Oncol       Date:  2008-06-20       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.